• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Primary Care
CMECNE

Epistaxis Management Practice Guidelines

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. List possible causes of epistaxis
2. Describe treatment options for anterior epistaxis

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 12/01/2022 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

SUMMARY:

The American Academy of Otolaryngology-Head and Neck Surgery Foundation has released evidence-based guidelines on the management of epistaxis. Usually spontaneous and without obvious cause, it is estimated that nosebleeds will occur in ≥ 60% of individuals in the US and approximately 6% require care. Usual source is the nasal septum, although lateral walls are also vascular and may be a source.

  • Possible secondary causes that require specific management: Systemic diseases and head and neck disorders including
    • Tumors of the nose or nasopharynx
    • Vascular malformations of the head and neck
    • History of recent facial trauma
    • History of nasal and/or sinus surgery within the previous 30 days
    • Hemorrhagic telangiectasia syndrome (HHT)
    • Leukemia
    • Liver disease
    • Coagulopathy
  • Medications: e.g., anticoagulant or antiplatelet drugs
  • Location
    • Anterior epistaxis is often manageable in the outpatient setting with the treatment plan described below | Can be visualizes with anterior rhinoscopy (nasal speculum) | 90% of epistaxis arises from anterior part of nasal septum
    • Posterior epistaxis is usually associated with brisk bleeding, may require acute hospital care | usually requires referral to specialist for endoscopy for visualization and treatment | Consider if bleeding not controlled with cautery or packing
  • Treatment Goals
    • Control acute bleeding
    • Prevent recurrence
    • Prevent complications due to treatments
  • First line treatments
    • Nasal compression
    • Topical vasoconstrictors
    • Moisturizing or lubricating agents
    • Nasal packing (resorbable and nonresorbable)
    • Nasal cautery (chemicals or electrocautery)
  • More complex management for minority of patients with refractory nosebleeds
    • Endoscopic arterial ligation
    • Interventional radiology

KEY POINTS:

Treatment of Active Bleeding

  • Apply firm, sustained compression to the lower third of the nose for ≥5 minutes (minimum)
    • Topical vasoconstrictors can aid in decreasing the bleeding
      • 0.05% oxymetazoline: Direct spray or soaked cotton
      • Epinephrine 1:1,000: soaked cotton (risk of systemic absorption and consequent tachycardia or elevated BP)
  • Perform anterior rhinoscopy to identify a source of bleeding after removing any blood clots (do not cauterize blindly)
    • Nasal cautery
      • Usually done using silver nitrate
      • Electrocautery is used for more severe cases
      • Cauterize first in a circular pattern around active site first before cauterizing active site
    • Moisturizing or lubricating agents may be helpful
  • If patient continues to have bleeding and source cannot be identified, apply nasal packing
    • Long duration for packing not advised | Time not specifically stated in the guidelines due to limited evidence | 48 hours reasonable and then reassess
    • Nasal packing (cotton stripping) impregnated with petrolatum (may come prepackaged) | Layer starting at floor of anterior nasal cavity (see AFP overview for more details in ‘Learn More – Primary Sources’ below)
      • Nasal tampons and nasal balloons also available
    • Some providers use antibiotics (oral or topical) but evidence is limited as to benefit
    • Patients at increased risk for bleeding due to medications
      • Use resorbable (i.e., absorbable, dissolvable) packing to avoid risk of bleeding that may occur upon removal of nonresorbable packing
      • Not necessary for patients taking low dose aspirin
  • Use the opportunity to identify risk factors for epistaxis including
    • Personal or family history that may indicate familial bleeding disorder
    • Intranasal drug use
    • Medications (anticoagulants, antiplatelet)
  • Recurrent bleeding (front line approaches not working)
    • Refer to specialist for nasal endoscopy to identify site and treat
    • May require surgical arterial ligation or endovascular embolization

Learn More – Primary Sources:

American Academy of Otolaryngology-Head and Neck Surgery Foundation Clinical Practice Guideline: Nosebleed (Epistaxis) Executive Summary

AFP: Epistaxis – Outpatient Management

Take a post-test and get CME credits

TAKE THE POST TEST

Get Guideline Notifications direct to your phone with ObGFirst™

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All Primary Care Posts
Next >

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site